What's new? Log in Free sign up

LENSAR (LNSR)

Company Profile

Company profile

Ticker

LNSR

Exchange

Website

CEO

Mr. Nicholas T. Curtis

Incorporated

Location

Fiscal year end

Sector

Health Care and Social Assistance > Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Stryker • FS KKR Capital • Boston Scientific • Solventum • Becton, Dickinson and • Blackstone Secured Lending Fund • Boardwalk Pipeline Partners • Domtar • Golub Capital BDC ...

Former names

LaserSoft Vision Inc, LensAR Inc

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

320125724

LNSR stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Quarterly report

7 Nov 24

LENSAR Reports Third Quarter 2024 Results and Provides Business Update

Submission of Matters to a Vote of Security Holders

Quarterly report

9 May 24

LENSAR Reports First Quarter 2024 Results and Provides Business Update

Departure of Directors or Certain Officers

Registration of securities for employees

LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Departure of Directors or Certain Officers

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Park West Asset Management LLC

Elizabeth G. O'Farrell

RICHARD L MD LINDSTROM

Financial summary

Financial statements Chart LNSR financial data

Quarter (USD)	Sep 24	Mar 24	Dec 23	Sep 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	10.44 mm	10.44 mm	10.44 mm	10.44 mm	10.44 mm	10.44 mm
Cash burn (monthly)	1.17 mm	1.25 mm	415.00 k	758.00 k	(no burn)	457.00 k
Cash used (since last report)	3.30 mm	3.53 mm	1.17 mm	2.13 mm	n/a	1.29 mm
Cash remaining	7.14 mm	6.92 mm	9.27 mm	8.31 mm	n/a	9.15 mm
Runway (months of cash)	6.1	5.5	22.3	11.0	n/a	20.0

Beta Read what these cash burn values mean

Financial data from LENSAR earnings reports.

Institutional ownership, Q2 2022

LNSR institutional ownership history Ownership history

53.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	36	37	-2.7%
Opened positions	3	3	–
Closed positions	4	7	-42.9%
Increased positions	11	7	+57.1%
Reduced positions	7	8	-12.5%

13F shares	Current	Prev Q	Change
Total value	40.17 mm	5.06 bn	-99.2%
Total shares	6.03 mm	6.11 mm	-1.3%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Park West Asset Management	1.08 mm	$7.04 mm	0.0%
Silver Point Capital	951.15 k	$6.19 mm	-9.7%
North Run Capital L P	914.51 k	$5.95 mm	+2.1%
Dimensional Fund Advisors	678.81 k	$4.42 mm	+0.3%
Madison Avenue Partners	676.11 k	$4.40 mm	0.0%
Vanguard	433.29 k	$2.82 mm	0.0%
Renaissance Technologies	351.30 k	$2.29 mm	+0.1%
DCF Advisers	296.52 k	$1.93 mm	+3.3%
BLK BlackRock	174.11 k	$1.13 mm	-1.0%
Millennium Management	102.96 k	$670.00 k	-5.6%

Largest transactions	Shares	Bought/sold	Change
Silver Point Capital	951.15 k	-102.24 k	-9.7%
North Run Capital L P	914.51 k	+18.85 k	+2.1%
XTX Topco	18.46 k	+18.46 k	NEW
Must Asset Management	0.00	-16.24 k	EXIT
Charles Schwab Investment Management	0.00	-11.55 k	EXIT
DCF Advisers	296.52 k	+9.50 k	+3.3%
Brandes Investment Partners	49.98 k	+7.01 k	+16.3%
Millennium Management	102.96 k	-6.14 k	-5.6%
Dimensional Fund Advisors	678.81 k	+2.19 k	+0.3%
BLK BlackRock	174.11 k	-1.77 k	-1.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

LNSR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
3 Sep 24	Gary M Winer	Common Stock	Buy	Acquire P	No	No	4.5	685	3.08 k	80,840
28 Aug 24	Gary M Winer	Common Stock	Buy	Acquire P	No	No	4.45	1,000	4.45 k	80,155
27 Aug 24	Gary M Winer	Common Stock	Buy	Acquire P	No	No	4.5	500	2.25 k	79,155
26 Aug 24	Gary M Winer	Common Stock	Buy	Acquire P	No	No	4.58	802	3.67 k	78,655
22 Aug 24	Gary M Winer	Common Stock	Buy	Acquire P	No	No	4.3	2	8.60	77,853
21 Aug 24	Gary M Winer	Common Stock	Buy	Acquire P	No	No	4.352	500	2.18 k	77,851
20 Aug 24	Gary M Winer	Common Stock	Buy	Acquire P	No	No	4.2	500	2.10 k	77,351
16 Aug 24	Gary M Winer	Common Stock	Buy	Acquire P	No	No	4.03	6	24.18	76,851
14 Aug 24	Gary M Winer	Common Stock	Buy	Acquire P	No	No	4.2	1,000	4.20 k	76,845
12 Aug 24	Gary M Winer	Common Stock	Buy	Acquire P	No	No	4.03	500	2.02 k	75,845

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

LENSAR Q3 2024 GAAP EPS $(0.13) Beats $(0.27) Estimate, Sales $13.539M Beat $11.500M Estimate

LENSAR (NASDAQ:LNSR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.27) by 51.85 percent. This is a 43.48 percent increase over losses of $(0.23) per share from the same

Press releases

From Benzinga Pro

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ORLANDO, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted four newly-hired

LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day

ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts,

LENSAR Reports Third Quarter 2024 Results and Provides Business Update

24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024 38% Revenue growth over

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.